You have accessJournal of UrologySexual Function/Dysfunction: Evaluation1 Apr 2016MP47-07 PREDIABETES, HYPOGONADISM & ERECTILE DYSFUNCTION: GLYCAEMIC CONTROL IN 109 HYPOGONADAL MEN TREATED WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) FOR UP TO 8 YEARS: REAL-LIFE DATA FROM REGISTRY STUDIES Aksam Yassin, Ahmad Haider, Karim Haider, Gheorghe Doros, Abdulmaged Traish, and Farid Saad Aksam YassinAksam Yassin More articles by this author , Ahmad HaiderAhmad Haider More articles by this author , Karim HaiderKarim Haider More articles by this author , Gheorghe DorosGheorghe Doros More articles by this author , Abdulmaged TraishAbdulmaged Traish More articles by this author , and Farid SaadFarid Saad More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.326AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Testosterone therapy (TRT) has been studied in hypogonadal men with type 2 diabetes mellitus (T2DM). However, there is no information on effects of TRT in hypogonadal men with prediabetes. Our aim was to study erectile function in hypogonadal men with prediabetes. METHODS From two registries of hypogonadal men receiving long-term TRT with TU, 109 men with prediabetes, defined as a baseline HbA1c from 5.7 to 6.4%, were analysed. TU was administered in 3-month intervals for up to 8 years. At each or each other visit, questionnaires were applied and anthropometric and metabolic parameters were measured. RESULTS Mean age was 57.37 ± 8.99 years. Total testosterone increased from 8.55 ± 2.14 to trough levels between 16 and 19 nmol/L. Mean IIEF-EF (maximum score: 30) improved from 13.04 ± 6.3 to 22.55 ± 4.74. The improvement was statistically significant for three years and remained statistically significant vs baseline throughout the observation time, and stable compared to previous years. Weight decreased from 96.15 ± 13.05 to 84.14 ± 6.98 kg by -14 ± 0.65%, waist circumference from 103.8 ± 6.88 to 94.32 ± 4.53 cm by -9.62 ± 0.44 cm (p<0.0001 for both). Fasting glucose decreased from 5.43 ± 0.68 to 4.63 ±0.67, change from baseline -0.94 ± 0.11 mmol/L reaching a plateau after 1 year. HbA1c decreased from 5.9 ± 0.21 to 5.38 ± 0.26%, change from baseline -0.59 ± 0.04% with statistical significance compared to the previous year for the first 3 years. The triglyceride:HDL ratio, considered a surrogate parameter of insulin resistance, declined from 5.62 ± 2.61 to 2.6 ± 0.74 (p<0.0001 for all). No patient progressed from prediabetes to T2DM. All but 4 patients′ last HbA1c was <5.7%. 3 patients dropped out, 2 due to relocation to a different city, 1 was lost to follow-up. There were no major adverse cardiovascular events during the full observation time. CONCLUSIONS Hypogonadal men with prediabetes showed clinically meaningful and sustainable weight loss and improvements in glycaemic control upon long-term TU treatment. No patient advanced from prediabetes to T2DM. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e629 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Aksam Yassin More articles by this author Ahmad Haider More articles by this author Karim Haider More articles by this author Gheorghe Doros More articles by this author Abdulmaged Traish More articles by this author Farid Saad More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...